R&D

New Twist on Potential Malaria Drug Target Acts by Trapping Parasites in Cells

Harvard School of Public Health (HSPH) researchers and colleagues seeking to block invasion of healthy red blood cells by malaria parasites have instead succeeded in locking the parasites within infected blood cells, potentially containing the disease. The findings reveal an essential step in the biology of the most common and severe malaria parasite, Plasmodium falciparum, and offer a new drug target for fighting one of the world's most common and dangerous infections.

Pharma CRM Goes on the iPad and iPhone

Media-Soft, CRM solutions provider for pharmaceutical companies, announced the launch of the native and offline iPhone adn iPad Pharma CRM application with advanced and unique features that increase the Sales Force effectiveness in pharma organizations.

Can a single, cheap pill combat cardiovascular disease?

Volunteers are being recruited in Ireland, the Netherlands and the UK to participate in a two-year trial of a single 'polypill' designed to prevent heart attack and stroke. The trials are financed in part by the UMPIRE (Use of a multidrug pill in reducing cardiovascular events) project, which has received EUR 3 million under the Health Theme of the Seventh Framework Programme (FP7).

Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America

Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion.

Nutrition in early years key to later health, EU-funded study shows

EU-funded research is revealing how nutrition in the womb and during our early years affects our risk of obesity, heart disease, lung disease and behavioural and cognitive problems in later years. Crucially, scientists from the EARNEST (Early nutrition programming) project have already translated many of their research findings into practical advice.

Anavex Reports Animal Study Results as Lead Alzheimer's Compound Approaches Phase 1 Clinical Trials

Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) reports promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease. ANAVEX 2-73 is the first of a new class of drugs that target mitochondrial dysfunction thought to be caused by oxidative stress to modify Alzheimer's disease.

The IT @ Networking Awards 2010

The goal of the IT @ Networking Awards 2010 (IT @ 2010), is to honour and promote outstanding healthcare IT solutions. The core aim of IT @ 2010 is to learn from the achievements of the very best IT installations on the globe. Healthcare systems face unprecedented challenges: high-tech, high-cost medicine; ageing populations; increased patient mobility; staff shortages; and a financial crisis. Intelligent IT solutions increase cost-effectiveness, productivity and safety and help healthcare facilities to confront these problems.

Research & Development

New Twist on Potential Malaria Drug Target Acts by Trapping Parasites in Cells

Pharma CRM Goes on the iPad and iPhone

Can a single, cheap pill combat cardiovascular disease?

Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America

Nutrition in early years key to later health, EU-funded study shows

Anavex Reports Animal Study Results as Lead Alzheimer's Compound Approaches Phase 1 Clinical Trials

The IT @ Networking Awards 2010

More Pharma News ...